| IUPAC name | propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate |
| inchi | InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1 |
| inchi key | GGXICVAJURFBLW-CEYXHVGTSA-N |
| molecular formula | C26H40O5 |
| synonyms | latanoprost130209-82-4XalatanPhXA41PHXA-41 |
| Compound Description | Latanoprost is a prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension. It has a role as an antiglaucoma drug, an antihypertensive agent, an EC 4.2.1.1 inhibitor and a prodrug. It is a prostaglandins Falpha, a triol and an isopropyl ester. It is functionally related to a latanoprost free acid.Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure . It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. Another benefit latanoprost is that it can be administered once a day.Latanoprost is a Prostaglandin Analog.Latanoprost is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.LATANOPROST is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996 and has 4 approved and 2 investigational indications.A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.See also: Latanoprost; netarsudil dimesylate ; Latanoprost; timolol maleate ; Latanoprost; netarsudil mesylate . |
